New Rhenium Radiopharmaceuticals for the Selective Imaging and Therapy of Breast Cancer
Annual rept. 12 May 1999-12 May 2000
NEW MEXICO STATE UNIV LAS CRUCES
Pagination or Media Count:
This report describes work completed on award number DAMDl7-97-l-7l20 during the third year of the project May 12, 1999- May 11, 2000. This project involves a fundamental investigation of new compounds and the development of new synthetic methodology for the imaging and radiotherapy of breast cancer with rhenium-188 labeled estradiol derivatives. Research efforts during the second year have focused on Technical Objective 3, as described in the original proposal text, and reproduced immediately below this paragraph. We have attained our goals of fully characterizing the estradiol-rhenium complexes, synthesized additional new classes of compounds, obtained results of receptor binding assays, determined an X-ray structure of an organoimidorhenium complex, investigated the solubility and stability of the complexes in water, and investigated reactions with different chemical species. We have published three papers describing portions of these results in Angewandte Chemie, Tetrahedron Letters, and Organometallics , copies of which are attached to the appendice of this report.
- Anatomy and Physiology
- Medicine and Medical Research